Brought to you by 
FivePrime raises $45mm in third round
16 Apr 2021
Executive Summary
FivePrime Therapeutics (protein drugs) raised $45mm in a third round financing led by Domain Associates. New investors HealthCap and JP Morgan Bay Area Equity Fund participated along with existing buyers Kleiner Perkins Caufield and Byers, Versant Ventures, Texas Pacific Group, Advanced Technology Ventures, the Wellcome Trust, Diamond Capital, and Singapore BioInnovations.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
FivePrime raises $45mm in third round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice